Skip to main content
. Author manuscript; available in PMC: 2014 Jan 20.
Published in final edited form as: Invest New Drugs. 2010 Sep 14;30(1):387–394. doi: 10.1007/s10637-010-9532-1

Table 1.

Baseline patient characteristics (N=35)

Characteristic Frequency
Enrollment location
 United States 23 (66%)
 Pacific 12 (34%)
Median age (Range) 61 yrs (21–77)
ECOG performance status
 0 11 (31%)
 1 23 (66%)
 2 1 (3%)
Male 28 (80%)
Race
 Asian 14 (40%)
 White 19 (54%)
 Black or African American 1 (3%)
 Unknown 1 (3%)
Primary disease site—Hepatic 31 (89%)
Locally advanced (vs Metastatic) 17 (49%)
Viral hepatitis 16 (46%)
History of chronic hepatitis 16 (46%)
Pathology
 Hepatocellular 32 (92%)
 Other 3 (8%)
Child-Pugh’s classification
 A 29 (85%)
 B 5 (15%)
Prior Therapy 7 (20%)
Types of prior therapy
 Chemoembolization 4 (57%)
 Surgical resection 1 (14%)
 Chemoembolization & radiofrequency
 ablation 1 (14%)
 Surgical resection & radiofrequency
 ablation 1 (14%)